Medical Oncology

Endocrinology

Questions discussed in this category

Does the presence of osteoporosis change the extent of workup that should be performed for an older patient with otherwise serologically low-risk MGUS?

Would your considerations change for a man vs a woman?

1 Answer available

How do you counsel patients on semaglutide or tirzepatide in light of potential cancer risks?

Do you avoid using these agents only in patients with history of medullary thyroid cancer or pancreatic cancer? Are there other cancer risks we should...

1 Answer available

Do you recommend progesterone for endometrial protection in a young woman on estrogen replacement therapy for iatrogenic menopause after definitive radiation therapy for locally advanced cervical cancer?

If so, what do you typically prescribe?

2 Answers available

Do patients with central adrenal insufficiency on maintenance hydrocortisone therapy require doubling of their corticosteroid during chemotherapy cycles?

1 Answer available

Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?

4 Answers available

How do you approach a young patient with metastatic poorly differentiated thyroid cancer with rhabdoid/non-anaplastic features?

4 Answers available

Aside from adrenal insufficiency and thyroid toxicities, how do you approach other hormonal imbalances during treatment with immune checkpoint inhibitors?

Have you encountered changes in prolactin, testosterone, etc?

1 Answer available

Are there any concerns with live vaccine innoculation and patients who are on denosumab?

1 Answer available

What factors aside from progression do you consider most important in determining whether a patient with metastatic papillary thyroid carcinoma is radioactive iodine refractory?

What is your evaluation approach for RAI response? What cumulative dose do you use in practice for deciding a patient is RAI refractory?

1 Answer available

Would you transition from denosumab to anabolic agents in patients who are in urgent need for extensive dental work?

2 Answers available

What endocrine therapy would you recommend to a premenopausal female with early stage HR+ Breast cancer who is transitioning from female to male and currently on testosterone?

1 Answer available

What is the goal of estradiol levels on ovarian suppression and AI for breast cancer?

Would you recommend aiming for the postmenopausal range as per the lab reference range or do you have a specific goal?

1 Answer available

In SIADH due to malignancy, do you prefer to use free water restriction or salt tablets?

Or other therapy - e.g., tolvaptan? Free water restriction may hinder QOL. Salt tablets may raise levels more quickly but have risks of edema and hype...

1 Answer available

Do you use denosumab for castration-sensitive prostate cancer with osseous metastases?

Only the mCRPC population was included in the Fizazi et al. study, but the FDA approval is for prevention of skeletal related events from any solid tu...

4 Answers available

When would you offer post-operative concurrent chemoradiation in anaplastic thyroid cancer?

Would you consider it for a patient with good PS but with limited metastatic disease? What dose fractionation would you prefer?

1 Answer available

How do you monitor risk of erythrocytosis from testosterone use for female to male transgender patients?

1 Answer available

How do you counsel cancer patients when they ask if they should avoid sugar?

9 Answers available

Are there any concerns regarding side effects in changing from denosumab to zolendronic acid or vice versa?

1 Answer available

Can denosumab be given every 3 months?

With studies showing non inferiority to zoledronic acid q 3 months in support of bone metastatic disease, would you consider extrapolating this data a...

1 Answer available

When treating patients with immune checkpoint inhibitors, do you routinely check markers of endocrinopathies such as TSH/ACTH, or only when a patient has symptoms?

If so, how often do you check these labs?

1 Answer available

Do you initiate management of new onset diabetes in a patient on immunotherapy or refer immediately to endocrinology given the risk of rapid worsening?

1 Answer available

How do you plan to use adjuvant denosumab in patients with hormone positive breast cancer given the survival advantage seen in the ABCSG-18 trial?

Do you look into their stage/risk to decide? Since patients can experience bone loss after stopping denosumab, how do you plan to discontinue?

1 Answer available

What is your approach to adjuvant hormone therapy for HR+ breast cancer in post-menopausal women with pre-existing osteoporosis?

Would you consider omitting treatment if small tumor and early stage? Or would you use tamoxifen?

2 Answers available

Do you offer adjuvant bisphosphonates to high-risk premenopausal women on ovarian suppression for early-stage breast cancer who would want to consider pregnancy in the future?

Which agents would you select and for how long would you treat them?

1 Answer available

For patients with mild CKD, how do you decide between zoledronic acid and denosumab for bone protection in patients with multiple myeloma?

For pts w/ eGFR between 30-60

1 Answer available

How do you incorporate denosumab into the surgical management of giant cell tumor of bone?

Does the degree of resectability affect your management?

2 Answers available

How do you manage anaplastic thyroid cancer that is progressing through radiation therapy?

2 Answers available

Do you avoid teriparatide in previously irradiated breast cancer patients with osteoporosis given the black box warning for potential risk of osteosarcoma?

1 Answer available

Do you routinely offer a bisphosphonate or denosumab to multiple myeloma patients without skeletal lesions?

Recommendations in guidelines are discordant (ASCO vs NCCN vs UptoDate).

2 Answers available

For patients on a bone-modifying agent for osteoporosis/severe osteopenia in the context of adjuvant AI therapy, how do you manage the bone-modifying agent once their AI course is complete?

1 Answer available

How would you approach patient with metastatic anaplastic thyroid cancer with NGS revealing only ARID1A mutation?

1 Answer available

For patients with cancer receiving a bone-modifying agent (bisphosphonate or denosumab) who suffer a fracture requiring stabilization or reconstruction, how do you manage the bone-modifying agent peri-operatively?

Is there concern for impaired healing? Do you pause therapy and for how long?

1 Answer available

Is there any role for bisphosphonate or alternative bone-modifying agents use in SMM in the absence of other indications for its use?

1 Answer available

Would you re-introduce bisphosphonate or denosumab in a bone-only metastatic ER+ breast cancer patient with history of osteonecrosis of the jaw?

2 Answers available

Do you give bisphosphonates after completing adjuvant anti-HER2 therapy and chemotherapy for HER2+ breast cancer to reduce the risk of recurrence?

2 Answers available

When is the best time to start denosumab in men with metastatic prostate cancer?

Should it be started at the initial diagnosis of bone mets?

2 Answers available

Is there a degree of osteoporosis (based on T-score) that would prohibit you from the utilization of an AI in a strong HR+ early stage breast cancer?

What factors if any would influence your decision and what would your approach be?

2 Answers available

What is your approach to the use of denosumab in patients with metastatic breast cancer with bony involvement?

Do you extrapolate the results of OPTIMIZE-2 and CALGB 70604 showing that an every 12 week dosing of zolendronic acid is noninferior to ever...

1 Answer available

How would you follow patients with differentiated thyroid cancer that no longer picks up iodine after thyroidectomy and RAI, and have thyroglobulin antibodies?

If a patient had a recurrence that was pathologically proven despite negative idodine scans, what imaging scans would you follow up with for surveilla...

1 Answer available

Based on the recent disease-free survival results from ABCSG-18 presented at San Antonio, do you favor the use of Denosumab in the adjuvant setting?

1 Answer available

Should bone-directed agents, such as denosumab or zoledronic acid, be given when patients are being treated with radium-223?

1 Answer available